| Authors: |
Navani V; Tom Baker Cancer Centre, Calgary, Canada. Electronic address: vishal.navani@albertahealthservices.ca., Wells JC; BC Cancer Agency, Vancouver, Canada., Boyne DJ; University of Calgary, Calgary, Canada., Cheung WY; Tom Baker Cancer Centre, Calgary, Canada; University of Calgary, Calgary, Canada., Brenner DM; University of Calgary, Calgary, Canada., McGregor BA; Dana Farber Cancer Institute, Boston, USA., Labaki C; Dana Farber Cancer Institute, Boston, USA., Schmidt AL; Dana Farber Cancer Institute, Boston, USA., McKay RR; University of California San Diego, Moores Cancer Center, La Jolla, United States., Meza L; City of Hope Comprehensive Cancer Center, Duarte, United States., Pal SK; City of Hope Comprehensive Cancer Center, Duarte, United States., Donskov F; University Hospital of Southern Denmark, Esbjerg, Denmark., Beuselinck B; University Hospitals Leuven, Leuven, Belgium., Otiato M; University of Michigan, Ann Arbor, USA., Ludwig L; Ipsen Biopharmaceuticals, Canada., Powles T; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Szabados BE; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Choueiri TK; Dana Farber Cancer Institute, Boston, USA., Heng DYC; Tom Baker Cancer Centre, Calgary, Canada. |
